Cytosorbents Corp Form 8-K December 26, 2017

I	IN	J	Π	1	F.	Г	)	S	Г	A	7	ויו	F.	ς	

#### SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 21, 2017

# **CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware 001-36792 98-0373793

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

7 Deer Park Drive, Suite K,

Monmouth Junction, New Jersey 08852

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 329-8885

Not	Αp	pli	ca	ble
100	4 <b>-</b> P	P	cu	010

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company "

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

### Item 8.01 Other Events.

On December 21, 2017, CytoSorbents Corporation (the "Company") issued a press release announcing that the U.S. Food and Drug Administration granted approval of the Company's REFRESH 2 Investigational Device Exemption application, subject to certain conditions related to requested clarifications and changes to the patient consent form and Instructions for Use document.

The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

# **Exhibit No. Description**

29.1 CytoSorbents Corporation Press Release, dated December 21, 2017.

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 22, 2017 CYTOSORBENTS CORPORATION

By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan President and

Title:

Chief Executive Officer